A 24-Week, Multi-Center, Open-Label Evaluation of Compliance and Tolerability of the Once-Daily 10 cm2 Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease.

Trial Profile

A 24-Week, Multi-Center, Open-Label Evaluation of Compliance and Tolerability of the Once-Daily 10 cm2 Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease.

Completed
Phase of Trial: Phase IV

Latest Information Update: 31 Mar 2017

At a glance

  • Drugs Rivastigmine (Primary)
  • Indications Alzheimer's disease
  • Focus Therapeutic Use
  • Acronyms CARE
  • Sponsors Novartis
  • Most Recent Events

    • 28 Mar 2013 Actual end date changed from Sep 2011 to Oct 2011 as reported by ClinicalTrials.gov.
    • 04 May 2012 Actual patient number is 380 as reported by ClinicalTrials.gov.
    • 04 May 2012 Actual end date (1 Sep 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top